Rheumatoid arthritis
Second line
Second-line DMARD in rheumatoid arthritis per 2022 after methotrexate. Dose 2–3 g daily in 2–3 doses after titration from 500 mg. The 2014 Cochrane meta-analysis showed efficacy comparable to methotrexate and . Often used in combination (methotrexate + sulfasalazine + – triple therapy) when monotherapy is insufficient. Effect develops over 2–3 months.